HFA Premium Access

Current pharmacological treatment of heart failure with mid-range ejection fraction

Event: Heart Failure 2021 Online Congress
Topic: Chronic Heart Failure
Session type: Symposium
Date: 29 June 2021
Time: 09:50 - 10:40

Session

Become an HFA member to access this resource

Become a member

Already a member? Sign in

4 presentations in this session

What is the evidence and which beta-blocker should a patient with HFmrEF receive?

Speaker: Professor A. Coats (Coventry, GB)
Thumbnail

What is the evidence and which aldosterone antagonist should a patient with HFmrEF receive?

Speaker: Professor F. Martinez (Cordoba, AR)
Thumbnail

What other pharmacological treatments should a patient with HFmrEF receive?

Speaker: Professor L. Lund (Stockholm, SE)
Thumbnail

Current pharmacological treatment of heart failure with mid-range ejection fraction - discussion.

Thumbnail

3 speakers from this session

Professor Andrew Coats

University of Warwick, Coventry (United Kingdom of Great Britain & Northern Ireland)
88 presentations
4 followers

Professor Felipe Martinez

State University of Cordoba, Cordoba (Argentina)
2 presentations
0 follower

Professor Lars Lund

Karolinska Institute, Stockholm (Sweden)
46 presentations
1 follower

Related content

ESC Premium Access

Heart failure with preserved ejection fraction: are there new options?

4 December 2021

ESC Premium Access

SGLT-2 inhibition: Winning battles in heart failure

3 December 2021

This platform is supported by

logo Novo Nordisk